:quality(90))
Pratia, a clinical research network operating across seven European countries, has been awarded Prime Site designation by IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry. Pratia has worked closely with IQVIA since 2014 to facilitate more equitable access to healthcare and improve the quality of life and safety of patients.
The IQVIA Prime Site program provides long-term strategic collaboration with hospitals characterized by clinical and technological excellence. Clinical trials that take place in the Prime Site Network adhere to the highest international ethical and regulatory standards.
In the last three years, the collaboration between Pratia and IQVIA has included 83 studies, with approximately 30 sites actively participating. It has played a pivotal role in supporting sponsors in their journey to bring cutting-edge treatments to patients in need, contributing to the development and approval of innovative medicines and therapies across various therapeutic areas. This collaboration will bring Pratia further innovative clinical research programs, for the benefit of patients, researchers and the national healthcare systems.
“This collaboration represents a significant milestone for us, as it enables us to offer new treatments through clinical research as a care option for our patients, but also allows us to further drive technological advancements in the industry. IQVIA’s renowned expertise in technology complements Pratia’s long-standing commitment to leveraging technology as a key driver for the future. By joining forces, we are better positioned to expedite the delivery of new treatments and enhance patient care and outcomes.” said Tomek Dabrowski, Chief Executive Officer, Pratia.
“The decision to award the status of IQVIA Prime Site to Pratia is in recognition of the long history of close collaboration and commitment to our patients and our shared customers. Moving forward, we will continue to evolve and deepen our relationship to bring improved healthcare outcomes to our patients.” stated Dean Summerfield, Senior Vice President, Real-World and Commercial Solutions, EMEA, IQVIA.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.
To learn more, visit www.iqvia.com.
:quality(90))